ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

CLLS Company Profile and Key Details

NASDAQ : CLLS

Cellectis S.A.

$1.26

-0.06-4.55%

At Close 4:00 PM

52.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

CLLS Stock Price Chart

Stock Price Today

Cellectis S.A. (CLLS) stock declined over -4.55%, trading at $1.26 on NASDAQ, down from the previous close of $1.32. The stock opened at $1.27, fluctuating between $1.25 and $1.29 in the recent session.

Stock Snapshot

1.32

Prev. Close

1.27

Open

126.12M

Market Cap

100.09M

Number of Shares

1.245

Day Low

1.285

Day High

-3.07

P/E Ratio

89.72%

Free Float in %

-0.41

EPS (TTM)

1.37

Book Value

-1.14

Cash Flow per Share

50.27K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2025	1.27	1.29	1.24	1.26	50.27K
Apr 01, 2025	1.25	1.33	1.23	1.32	191.73K
Mar 31, 2025	1.26	1.26	1.16	1.24	152.61K
Mar 28, 2025	1.27	1.29	1.25	1.27	85.69K
Mar 27, 2025	1.33	1.33	1.29	1.30	96.49K
Mar 26, 2025	1.33	1.33	1.29	1.30	87.63K
Mar 25, 2025	1.31	1.35	1.28	1.31	123.8K
Mar 24, 2025	1.30	1.32	1.29	1.31	155.63K
Mar 21, 2025	1.27	1.30	1.27	1.30	99.3K
Mar 20, 2025	1.25	1.31	1.25	1.27	172.72K
Mar 19, 2025	1.26	1.31	1.25	1.31	222.9K
Mar 18, 2025	1.27	1.29	1.24	1.27	234.21K
Mar 17, 2025	1.22	1.23	1.19	1.23	549.4K
Mar 14, 2025	1.40	1.40	1.14	1.24	13.94M
Mar 13, 2025	1.30	1.33	1.27	1.29	141.45K
Mar 12, 2025	1.28	1.31	1.22	1.30	121.47K
Mar 11, 2025	1.28	1.32	1.22	1.25	137.7K
Mar 10, 2025	1.26	1.29	1.20	1.22	152.51K
Mar 07, 2025	1.28	1.31	1.25	1.25	48.8K
Mar 06, 2025	1.25	1.27	1.22	1.22	42.4K

Contact Details

Paris, 75013

France

Website: https://www.cellectis.comContact: 331 816 91600

About Company

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Frequently Asked Questions

What is the current Cellectis S.A. (CLLS) stock price?

Cellectis S.A. (NASDAQ: CLLS) stock price is $1.26 in the last trading session. During the trading session, CLLS stock reached the peak price of $1.29 while $1.25 was the lowest point it dropped to. The percentage change in CLLS stock occurred in the recent session was -4.55% while the dollar amount for the price change in CLLS stock was -$0.06.

CLLS's industry and sector of operation?

The NASDAQ listed CLLS is part of Biotechnology industry that operates in the broader Healthcare sector. Cellectis S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLLS?

Ms. Kyung Nam-Wortman
Executive Vice President & Chief HR Officer
Ms. Marie-Bleuenn Terrier
Gen. Counsel & Sec. of the Board of Directors
Dr. Andre Choulika Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. David J. D. Sourdive Ph.D.
Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Directorr
Dr. Bing C. Wang M.B.A., Ph.D.
Chief Financial Officer
Valerie Cros
Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat
Chief Technological Officer
Dr. Philippe Duchateau Ph.D.
Chief Scientific Officer
Mr. Stephan Reynier M.Sc., MSc
Chief Regulatory & Pharmaceutical Compliance Officer
Pascalyne Wilson
Director of Communications

How CLLS did perform over past 52-week?

CLLS's closing price is 10.53% higher than its 52-week low of $1.14 where as its distance from 52-week high of $3.38 is -62.72%.

How many employees does CLLS have?

Number of CLLS employees currently stands at 216.

Link for CLLS official website?

Official Website of CLLS is: https://www.cellectis.com

How do I contact CLLS?

CLLS could be contacted at phone 331 816 91600 and can also be accessed through its website. CLLS operates from 8, rue de la Croix Jarry, Paris, 75013, France.

How many shares of CLLS are traded daily?

CLLS stock volume for the day was 50.27K shares. The average number of CLLS shares traded daily for last 3 months was 396.47K.

What is the market cap of CLLS currently?

The market value of CLLS currently stands at $126.12M with its latest stock price at $1.26 and 100.09M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	216
Beta	3.28
Sales or Revenue	$19.17M
5Y Sales Change%	-0.954%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology